I would also like to remind you that remarks made on this call that are not historical in nature may be forward-looking statements about Regeneron and are subject to a number of risks and uncertainties. Actual events and our actual results may differ materially. Such remarks may include but are not limited to those related to Regeneron and its products and business, sales forecasts, financial forecasts, development programs, collaborations, finances, regulatory matters, intellectual property and competition, all of which involve a number of risks and uncertainties. A more complete description of these and other material risks can be found in Regeneron’s filings with the United States Securities and Exchange Commission, or SEC, including its Form 10-K for the year ended December 31, 2011 and Form 10-Q for the quarter ended June 30, 2012 which we filed this morning. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise, unless required by law.
GAAP and non-GAAP measures will be discussed on today’s call. Information regarding our use of non-GAAP financial measures and a reconciliation of these measures to GAAP are available in our financial results press release, which can be accessed on our website. Once our call concludes, myself and the IR team will be available to answer further questions.
With me, let me turn the call over to our President and Chief Executive Officer, Dr. Len Schleifer.
Dr. Leonard SchleiferThanks, Michael. Good morning to everyone. In terms of the agenda for today, following my brief introductory remarks, George Yancopoulos, Chief Scientific Officer, will provide an update on our pipeline. Bob Terifay, Senior Vice President of Commercial, will then provide an update on the EYLEA launch, and Murray Goldberg, our Chief Financial Officer will wrap up with financial highlights before I offer some concluding remarks and we open the call for questions and answers.